2/20/2013

Osiris Therapeutics now holds the orphan-drug designation in Europe for its stem cell treatment Prochymal for acute graft-versus-host disease in bone marrow transplant patients. The move will make it easier for Osiris to secure a partnership or sale.

Related Summaries